Ric3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
| symbol = RIC3
| name = Acetylcholine Receptor Chaperone 3
| chromosome = 5
| locus = 5p15.2
| geneID = 57180
| omim = 608977
| ensembl = ENSG00000166402
| uniprot = Q86XR7
| uniprot_name = RIC3
| diseases = Myasthenia Gravis, Epilepsy, Autism Spectrum Disorder
| diseases_ref = Halff et al., 2019, Nat Neurosci
}}
RIC3 (Resistance to inhibitors of cholinesterase 3) is a protein that functions as a molecular chaperone involved in the assembly and trafficking of nicotinic acetylcholine receptors (nAChRs). The RIC3 gene is located on chromosome 7p14.3 and encodes a protein of 461 amino acids. Originally identified in C. elegans as a gene conferring resistance to cholinesterase inhibitors, RIC3 facilitates the folding and assembly of nAChR subunits (particularly α7 and α4β2 subtypes) in the endoplasmic reticulum and their transport to the plasma membrane. In the nervous system, RIC3 is expressed in neurons and supports synaptic cholinergic signaling. RIC3 is implicated in myasthenia gravis, epilepsy, and autism spectrum disorder due to its role in nAChR function.
RIC3 (Resistant to Inhibitors of Cholinesterase 3) is a transmembrane chaperone protein that plays a critical role in the assembly and trafficking of nicotinic acetylcholine receptors (nAChRs). RIC3 is essential for the proper folding and surface expression of various nAChR subtypes.
RIC3 facilitates:
RIC3 is particularly important for:
At cholinergic synapses, RIC3 ensures:
RIC3 variants may contribute to myasthenia gravis through:
RIC3 mutations are associated with epilepsy through:
RIC3 variants have been linked to ASD through:
RIC3 is expressed in:
In the brain, RIC3 is found in:
The study of Ric3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cherian A, K P D, Vijayaraghavan A. "Parkinson's disease - genetic cause." Current opinion in neurology (2023) DOI:10.1097/WCO.0000000000001167
Yadav N, Thelma BK. "Deletion induced splicing in RIC3 drives nicotinic acetylcholine receptor regulation with implications for endoplasmic reticulum stress in human astrocytes." Glia (2023) DOI:10.1002/glia.24333
Sudhaman S et al.. "Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson's disease with non-motor phenotypes." Journal of medical genetics (2016) DOI:10.1136/jmedgenet-2015-103616
Chiappelli F et al.. "Regulation of inflammaging." Bioinformation (2025) DOI:10.6026/973206300210571
Pradhan A et al.. "Unraveling the molecular interactions between α7 nicotinic receptor and a RIC3 variant associated with backward speech." Cellular and molecular life sciences : CMLS (2024) DOI:10.1007/s00018-024-05149-8
Mizrachi T et al.. "Neuroinflammation Modulation via α7 Nicotinic Acetylcholine Receptor and Its Chaperone, RIC-3." Molecules (Basel, Switzerland) (2021) DOI:10.3390/molecules26206139
Noonan JD, Beech RN. "Two residues determine nicotinic acetylcholine receptor requirement for RIC-3." Protein science : a publication of the Protein Society (2023) DOI:10.1002/pro.4718
Treinin M et al.. "Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway." Central nervous system agents in medicinal chemistry (2017) DOI:10.2174/1871524916666160829114533